Monday, January 01, 2007 8:00:00 AM PDT | VentureDeal Staff
RI -- Eschewing the
venture capital model, biotech company EpiVax
has had success so far by funding its development work with contract testing
for big pharma.
The company aims to "be the industry leader in computational immunology,
vaccine design and immunogenicity expertise." It hires itself out to
large pharmaceutical companies who need testing services and obtains grants
from government sources to develop vaccines.
The surplus from these and other activities is used to fund "internal
discovery and design efforts aimed at selected biological targets, retaining a
larger economic interest in the subsequently out-licensed lead candidates."
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
© 2016 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.